α-it

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

Tengonermin (ARENEGYR), a vascular-targeting compound, comprises human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. It enhances intratumoral chemotherapy delivery and T-cell infiltration by altering the tumor microenvironment [1] [2].

Suvratoxumab (MEDI4893) is a high-affinity, long-acting humanized IgG1κ anti-α-toxin monoclonal antibody. It effectively neutralizes α-toxin, a principal virulence factor of S. aureus, enhancing survival and diminishing lung injury in an immunocompromised mouse model of pneumonia. Additionally, Suvratoxumab augments the antibacterial efficacy of Vancomycin and Linezolid [1] [2] [3].

Farletuzumab ecteribulin (MORAb-202) is a highly cytotoxic antibody-drug conjugate (ADC) targeting human folate receptor alpha (FRA). This ADC comprises the humanized Farletuzumab antibody linked to Mal-PEG2-Val-Cit-PAB-eribulin through reduced interchain disulfide bonds, with an agent-to-antibody ratio of 4.0, demonstrating potent antitumor activity against FRA-positive cells in vitro.

Ifinatamab is a monoclonal immunoglobulin G1-kappa antibody that targets the human B7-H3 protein (B7 homolog 3). It functions as a glycoform α immunomodulator [1].

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.